Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia

Abstract

Objective To evaluate the effects of treatment with risperidone and aripiprazole on serum prolactin, testosterone and estradiol levels in female patients with schizophrenia in China.

Methods In the retrospective study, Data were collected and included prolactin, testosterone and estradiol levels of 30 female patients with risperidone monotherapy. In the prospective study, Another 30 female schizophrenic patients were randomized to receive risperidone or adjunctive aripiprazole for six weeks. Serum prolactin, testosterone and estradiol levels were measured.

Results Serum prolactin, testosterone and estradiol levels in both studies were significantly decreased after risperidone treatment compared with baseline (P<0.05), and prolactin levels remained at a high level. Serum prolactin levels in the adjunctive aripiprazole group were significantly decreased after treatment compared with baseline in the prospective study (P<0.05). Doses of 5 mg and 10 mg of adjunctive aripiprazole achieved the same efficacy at the end of treatment.

Conclusions Risperidone treatment decreased serum testosterone and estradiol levels. Adjunctive aripiprazole relieved hyperprolactinemia, but had no effect on testosterone or estradiol levels. Adjunctive aripiprazole at a dose of 5 mg is recommended for clinical use.

Key words

schizophrenia - risperidone - aripiprazole - prolactin - testosterone - estradiol

• References

• 1 Comptom 3rd WM, Helzer JE, Hwu HG. et al. New methods in cross-cultural psychiatry: Psychiatric illness in Taiwan and the United States. Am J Psychiatry 1991; 148: 1697-1704
• 2 Potkin SG, Saha AR, Sa Kujawa MJ. et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-690
• 3 Litman RE, Su TP, Potter WZ. et al. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 1996; 168: 571-579
• 4 Leucht S, Cipriani A, Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
• 5 Cohen LJ. Risperidone. Pharmacotherapy 1994; 14: 253-265
• 6 Burris KD, Molski TF, Xu C. et al. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-389
• 7 Keck Jr PE, McElroy Sl. Aripiprazole: A partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2013; 12: 655-662
• 8 Bowles TM, Levin GM. Aripiprazole: A new atypical antipsychotic drug. Ann Pharmacother 2003; 37: 687-694
• 9 Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?. Ann Clin Biochem 2010; 47: 292-300
• 10 Chen JX, Su YA, Bian QT. et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015; 58: 130-140
• 11 Ziadi Trives M, Bonete Llácer JM, García Escudero MA. et al. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol 2013; 33: 538-541
• 12 Li H, Luo J, Wang C. et al. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: A randomized, double-blind, active parallel-controlled, multicenter clinical trial. Schizophr Res 2014; 157: 112-119
• 13 Yasui-Furukori N, Furukori H, Sugawara N. et al. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in femal patients with schizophrenia. J Clin Psychopharmacol 2010; 30: 596-599
• 14 Kinon BJ, Gilmore JA, Liu H. et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychoticmedications or risperidone. Psychoneuroendocrinolog 2003; 28: S109-S123
• 15 Qiao Y, Yang F, Li C. et al. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Psychiatry Res 2016; 237: 83-89
• 16 Halbreich U, Kinon BJ, Gilmore JA. et al. Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28 (Suppl. 01) 53-67
• 17 Zhang B, Deng L, Wu H. et al. Relationship between long-term use of a typical antipsychotic medication by Chinese schizophreniapatients and the bone turnover markers serum osteocalcin and β-CrossLaps. Schizophr Res 2016; 176: 259-263
• 18 Petty RG. Prolactin and antipsychotic medications:mechanism of action. Schizophr Res 1999; 35: 67-73
• 19 Tourrone P, Kapur S, Seeman MV. et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159: 133-135
• 20 Volavka J, Czobor P, Cooper TB. et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperilol. J Clin Psychiatry 2004; 65: 57-61
• 21 Rainka MM, Capote HA, Ross CA. et al. Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole. J Clin Pharm Ther 2009; 34: 595-598
• 22 Lee BJ, Lee SJ, Kim MK. et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated withrisperidone. Clin Psychopharmacol Neurosci 2013; 11: 60-66
• 23 Shores LE. Normalization of risperidone-induced hyperprolactinemia with the addition of aripiprazole. Psychiatry 2005; 2: 42-45
• 24 Chen CY, Lin TY, Wang CC. et al. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: A case series. Psychiatry Clin Neurosci 2011; 65: 95-97
• 25 Ranjbar F, Sadeghi-Bazargani H, Niari Khams P. et al. Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. Neuropsychiatr Dis Treat 2015; 11: 549-555
• 26 Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999; 288: 774-781